Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 211-662-7 | CAS number: 682-11-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
The potential mutagenicity of 2 -allyloxymethyl-2 -ethylpropanediol in bacterial cells has been assessed in a bacterial reverse mutation assay (Ames test) conducted according to OECD Test Guideline 471 using the test substance trimethylolpropane monoallyl ether (TMPME). No evidence of mutagenicity was observed in the test using strains of S. typhimurium and E. coli,with or without metabolic activation(Sokolowski, 2006).
There are no studies available on the genotoxicity of 2 -allyloxymethyl-2 -ethylpropanediol in mammalian test systems. Based on existing datasets and structural and chemical considerations, read-across from 2 -allyloxymethyl-2 -ethylpropanediol to mammalian genotoxicity studies on 2,2 -bis(allyloxymethyl)butan-1 -ol is appropriate to meet the REACH Annex VII-IX data requirements. Read-across is scientifically justified and also enables the REACH requirements to be adequately addressed, while avoiding unnecessary animal testing in accordance with EU Directive 86/609/EEC.
The potential for 2,2 -bis(allyloxymethyl)butan-1 -ol to induce gene mutations in mammalian cells was assessed in a modern guideline-compliant mouse lymphoma assay (OECD TEST Guideline 476) conducted using the test substance trimethylolpropane diallyl ether (TMPDE; Riach, 2010). No evidence of mutagenicity was seen in the absence of metabolic activation. Weak responses (meeting the laboratory's criteria for a positive response) were seen in the presence of metabolic activation at higher concentrations. Positive responses were associated with marked cytotoxicity (relative total growth of 8 -15%). The report authors note a preponderance of small type colonies at these concentrations, indicating that the activity of TMPDE in this study is associated with large-scale (i.e. chromosomal) damage rather than deletions and/or point mutations. The authors further conclude that, while this result is insufficient evidence on its own to classify the substance as mutagenic according to GHS Category 2, it would contribute towards a Category 2 classification if supported by positive findings from relevant in vivo tests.
The results of the mouse lymphoma assay indicate that TMPDE is clastogenic in vitro, in the presence of metabolic activation but only at concentrations associated with marked cytotoxicity (Riach, 2010). Further studies of chromosomal aberration in vitro are not available, however, the substance has been investigated in a higher tier (in vivo) study.
The genotoxicity 2,2 -bis(allyloxymethyl)butan-1 -ol was assessed in a micronucleus test in male and female mice, according to OECD Test Guideline 474 using the test substance TMPDE (Herbold, 1993). In the study, the mice received a single intraperitoneal injection of the test substance at a dose level of 1250 mg/kg bw in corn oil. Vehicle controls and positive controls (cyclophosphamide) were included. The treated mice were sacrificed at 16, 24 and 48 hours after administration. All treated mice survived to sacrifice, however all showed signs of toxicity. There was an altered ratio between polychromatic and monochromatic erythrocytes. No evidence of a clastogenic effect was found in this study. The response to the positive control (CPA) confirmed the sensitivity of the assay.
The negative findings in the mouse micronucleus study therefore indicate that 2,2 -bis(allyloxymethyl)butan-1 -ol is not clastogenic in vivo. Based on read-across to the mammalian mutagenicity studies, 2 -allyloxymethyl-2 -ethylpropanediol is not predicted to have mutagenic potential.
Justification for selection of genetic toxicity endpoint
No study was selected since negative results were obtained in an in vitro study using 2 -allyloxymethyl-2 –ethylpropanediol and in an in vitro and an in vivo study using the read-across substance: 2,2 -bis(allyloxymethyl)butan-1 –ol.
Short description of key information:
No evidence of mutagenicity was seen for 2-allyloxymethyl-2-ethylpropanediol in a bacterial reverse mutation assay (Ames test). Based on available datasets and chemical and structural considerations, read across from 2-allyloxymethyl-2-ethylpropanediol to mammalian in vitro genotoxicity studies on 2,2-bis(allyloxymethyl)butan-1-ol is appropriate to address the REACH Annex VII-IX data requirements. In a mouse lymphoma assay, a weak positive response was reported in the presence of metabolic activation and only at concentrations associated with marked cytogenicity. No evidence of clastogenicity was seen in a standard mouse micronucleus assay.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
2 -allyloxymethyl-2 -ethylpropanediol is not mutagenic in bacterial cells in vitro. Based on read-across to a genotoxicity study on 2,2 -bis(allyloxymethyl)butan-1 -ol in mammalian cells in mice, 2 -allyloxymethyl-2 -ethylpropanediol is not predicted to have genotoxic potential in vivo. The substance does not meet the criteria for classification for genotoxicity according to Directive 67/548/EEC or Regulation 1272/2008/EC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
